This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the Phase 3 POD1UM-303/InterAACT2 Trial Results for Retifanlimab (Zynyz) in Squamous Cell Anal Carcinoma (SCAC) from Incyte (INCY)

Ticker(s): INCY

Who's the expert?

An oncologist specializing in gastrointestinal cancers, particularly anal and rectal cancers, with experience in immunotherapy and checkpoint inhibitors. The expert should have knowledge of clinical trials related to PD-1 inhibitors and be familiar with the challenges of treating metastatic SCAC.

Interview Questions
Q1.

The POD1UM-303/InterAACT2 trial demonstrated a 37% reduction in the risk of progression or death (PFS) for patients treated with retifanlimab and chemotherapy compared to chemotherapy alone. How significant is this improvement for patients with advanced SCAC, considering the lack of FDA-approved treatments for this condition?

Added By: slingshot_insights
Q2.

The trial showed an approximately 6-month improvement in overall survival (OS) for patients treated with retifanlimab and chemotherapy, with a trend toward statistical significance. Could you elaborate on the potential impact of this OS extension for patients with inoperable SCAC?

Added By: slingshot_insights
Q3.

The overall response rate (ORR) and duration of response (DOR) were both improved with the addition of retifanlimab. What does this mean for the quality of life and disease management in these patients?

Added By: slingshot_insights
Q4.

Retifanlimab was generally well-tolerated, with a safety profile consistent with other checkpoint inhibitors. Given the chronic nature of SCAC and its recurrence, how important is the tolerability of this combination therapy for long-term patient care?

Added By: slingshot_insights
Q5.

SCAC remains a rare and neglected disease with an increasing incidence, particularly among patients with HIV. How does the potential approval of retifanlimab address the current gaps in treatment for this high-risk population?

Added By: slingshot_insights
Q6.

Considering that platinum-based chemotherapy has been the standard treatment for decades, how do these results position retifanlimab in potentially reshaping the treatment paradigm for metastatic or recurrent SCAC?

Added By: slingshot_insights
Q7.

Patients with well-controlled HIV were included in the study. How might retifanlimab offer new hope for HIV-positive patients, who are disproportionately affected by SCAC, in terms of efficacy and safety?

Added By: slingshot_insights
Q8.

Incyte plans to file a supplemental Biologics License Application (sBLA) for retifanlimab by the end of 2024. What are the critical steps Incyte must take to secure regulatory approval, and how might this drug influence the treatment landscape for SCAC globally?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained
9Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.